Human papillomavirus 59 (HPV59) is a high-risk type of Alphapapillomavirus with a circular double-stranded DNA genome. It infects the mucosal epithelium of the anogenital tract. Persistent infection with HPV59 can contribute to oncogenesis, although it is relatively uncommon.
Virology & Oncogenic Mechanisms
HPV59 is one of the high‑risk human papillomavirus types recognised by cancer research organisations. The approximately 8 kb genome encodes early proteins (E1–E7) and late structural proteins (L1–L2). Oncoproteins E6 and E7 promote degradation of the p53 and retinoblastoma tumour suppressor proteins, facilitating cell cycle progression and inhibiting apoptosis. The virus gains entry by binding heparan sulfate proteoglycans and infects basal keratinocytes via microabrasions. The viral genome is maintained as an episome and replicates as the host cells differentiate; integration of HPV59 DNA with constitutive E6/E7 expression can lead to malignant transformation. While HPV16 and HPV18 are responsible for most HPV‑related cancers, other high‑risk types such as 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 also contribute to cervical carcinogenesis.
Clinical Impact and Prevention
HPV59 infection is relatively rare but has been detected in high‑grade squamous intraepithelial lesions and a small proportion of invasive cervical cancers. It may also be present in cancers of the vulva, vagina, anus and penis. Most HPV59 infections are transient and are cleared by the immune system, but persistence increases the risk of neoplastic progression, particularly in smokers and individuals with immunosuppression. Current prophylactic vaccines do not include HPV59, so prevention relies on behavioural measures and early detection. Regular cervical screening using Pap cytology and high‑risk HPV DNA testing enables identification and monitoring of HPV59 infections. Using barrier methods, reducing the number of sexual partners and smoking cessation help to limit persistent infection. HPV59 is a high‑risk papillomavirus that can contribute to cervical and other anogenital cancers despite its low prevalence. Screening and risk reduction are critical because vaccines do not currently target this type. Related Terms: HPV45, HPV56, High‑risk HPV, Pap test, Viral integration